Diagnostic test for cervical cancer screening - Methica CC kit

Cervical cancer is a disease that can almost always be prevented by adequate screening. However, current screening methods are not sufficiently accurate, which means that every year one million European women are wrongly suspected of having cervical cancer. This leads to a lot of stress, stigmatisation and unnecessary healthcare costs.

This project concerns the development of a working prototype, testing of the Methica CC kit (an innovative diagnostic test) in a laboratory environment and validation by the Notified Body.

The test is developed from new biomarkers discovered and patented by Bea Wisman and Ed Schuuring (UMCG researchers). CC Diagnostics embraces this knowledge and brings it to the market. The Methica CC kit is able to reduce the number of false positive results by 33%. This has a huge human and social impact because unnecessary long-term stress in women who falsely test positive is prevented and early detection of cancer is improved. Furthermore, substantial savings on healthcare resources can be achieved. Finally, the Methica CC kit can also be performed by women themselves, allowing them to fully participate in the population screening without having to visit their GP.

Because CC Diagnostics collaborates with local parties and the development largely takes place in the region, the Groningen ecosystem is given a boost. SNN supports CC Diagnostics by accelerating this innovation and thus contributes to a healthy and sustainable society.